UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers

Alnuaimi, Alya R; Nair, Vidhya A; Malhab, Lara J Bou; Abu-Gharbieh, Eman; Ranade, Anu Vinod; Pintus, Gianfranco; Hamad, Mohamad; ... Abdel-Rahman, Wael M; + view all (2022) Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers. World Journal of Gastrointestinal Oncology , 14 (9) pp. 1637-1653. 10.4251/wjgo.v14.i9.1637. Green open access

[thumbnail of Emerging role of caldesmon in cancer A potential biomarker for colorectal cancer and other cancers.pdf]
Preview
PDF
Emerging role of caldesmon in cancer A potential biomarker for colorectal cancer and other cancers.pdf - Published Version

Download (954kB) | Preview

Abstract

Colorectal cancer (CRC) is a devastating disease, mainly because of metastasis. As a result, there is a need to better understand the molecular basis of invasion and metastasis and to identify new biomarkers and therapeutic targets to aid in managing these tumors. The actin cytoskeleton and actin-binding proteins are known to play an important role in the process of cancer metastasis because they control and execute essential steps in cell motility and contractility as well as cell division. Caldesmon (CaD) is an actin-binding protein encoded by the CALD1 gene as multiple transcripts that mainly encode two protein isoforms: High-molecular-weight CaD, expressed in smooth muscle, and low-molecular weight CaD (l-CaD), expressed in nonsmooth muscle cells. According to our comprehensive review of the literature, CaD, particularly l-CaD, plays a key role in the development, metastasis, and resistance to chemoradiotherapy in colorectal, breast, and urinary bladder cancers and gliomas, among other malignancies. CaD is involved in many aspects of the carcinogenic hallmarks, including epithelial mesenchymal transition via transforming growth factor-beta signaling, angiogenesis, resistance to hormonal therapy, and immune evasion. Recent data show that CaD is expressed in tumor cells as well as in stromal cells, such as cancerassociated fibroblasts, where it modulates the tumor microenvironment to favor the tumor. Interestingly, CaD undergoes selective tumor-specific splicing, and the resulting isoforms are generally not expressed in normal tissues, making these transcripts ideal targets for drug design. In this review, we will analyze these features of CaD with a focus on CRC and show how the currently available data qualify CaD as a potential candidate for targeted therapy in addition to its role in the diagnosis and prognosis of cancer.

Type: Article
Title: Emerging role of caldesmon in cancer: A potential biomarker for colorectal cancer and other cancers
Location: China
Open access status: An open access version is available from UCL Discovery
DOI: 10.4251/wjgo.v14.i9.1637
Publisher version: http://dx.doi.org/10.4251/wjgo.v14.i9.1637
Language: English
Additional information: © The Author 2023. Original content in this paper is licensed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) Licence (https://creativecommons.org/licenses/by/4.0/).
Keywords: Bladder cancer, CALD1, Caldesmon, Chemoresistance, Colorectal cancer, Gastric cancer, Glioma, Epithelial to mesenchymal transition, Invasion, Metastasis
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci
URI: https://discovery.ucl.ac.uk/id/eprint/10167928
Downloads since deposit
28Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item